Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug

Phase I Shows Promise, But ION449 Must Catch Up With Inclisiran

Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.

Cholesterol plaque in artery
Ionis and AstraZeneca's anti-PCSK9 drug shows promise in Phase I • Source: Shutterstock

Early data from the latest gene silencing-based drug targeting PCSK9 show a medicine with potentially strong efficacy in patients, but one that also faces some significant competitive hurdles, particularly as Alnylam Pharmaceuticals Inc./Novartis AG are poised to have the first-in-class advantage with inclisiran. However, Ionis Pharmaceuticals, Inc.’s ION449 may be able to catch up via the accelerated development plan that partner AstraZeneca PLC has in store for the drug, and it has a potential oral version in preclinical development.

AstraZeneca presented data from the Phase I study of ION449, also known as AZD8233, in a poster session at the American Heart Association’s 2020 conference. The drug is described as a generation 2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.